4/25
07:00 am
hrow
Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024
Low
Report
Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024
4/11
08:00 am
hrow
Harrow Health, Inc. (NASDAQ: HROW) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $24.00 price target on the stock.
Neutral
Report
Harrow Health, Inc. (NASDAQ: HROW) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $24.00 price target on the stock.
4/2
08:16 am
hrow
Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing
Low
Report
Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing
3/25
08:07 am
hrow
Harrow Health, Inc. (NASDAQ: HROW) had its price target lowered by analysts at B. Riley from $30.00 to $26.00. They now have a "buy" rating on the stock.
Medium
Report
Harrow Health, Inc. (NASDAQ: HROW) had its price target lowered by analysts at B. Riley from $30.00 to $26.00. They now have a "buy" rating on the stock.
3/21
10:01 am
hrow
Harrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Harrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/19
05:45 pm
hrow
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
High
Report
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
3/5
07:00 am
hrow
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024
Low
Report
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024
2/15
04:01 pm
hrow
Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
Medium
Report
Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
1/29
07:00 am
hrow
Harrow Announces New Appointments to its Board of Directors
Medium
Report
Harrow Announces New Appointments to its Board of Directors